Skip to content

Evaluation of Membrane Lung Function in High-altitude Regions

Evaluation of Membrane Lung Function for Patients Receiving Venovenous Extracorporeal Membrane Oxygenation in High-altitude Regions

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06152744
Enrollment
40
Registered
2023-12-01
Start date
2023-12-05
Completion date
2025-12-31
Last updated
2025-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracorporeal Membrane Oxygenation, High Altitude, Membrane Lung Function

Brief summary

Over the last 20 years, extracorporeal membrane oxygenation (ECMO) has been used to support adult patients with respiratory or cardiac failure who are unlikely to survive conventional treatment methods. ECMO circuit, pump, and oxygenator technology improvements permit safer perfusion for extended periods. The prolonged use of an ECMO circuit increases the risk of membrane lung (ML) dysfunction. The ML is responsible for taking in oxygen and removing carbon dioxide. The non-biologic surface of the ML triggers inflammatory and coagulation pathways, resulting in the formation of blood clots, breakdown of fibrin, and activation of white blood cells, which ultimately leads to ML dysfunction. Coagulation and fibrinolysis activation can cause systemic coagulopathy or hemolysis, and the deposition of blood clots can block blood flow. Moreover, the accumulation of moisture in the gas phase and the buildup of protein and cellular debris in the blood phase may contribute to shunt and dead-space physiology, respectively, impairing the exchange of gases. These three categories-hematologic abnormalities, mechanical obstruction, and inadequate gas exchange-account for most ML exchanges. Worsening oxygenation during ECMO should prompt quantification of oxygen transfer. ML exchange is indicated when the ML can no longer meet the patient's oxygen demand. The partial pressure of Post-ML arterial oxygen less than 200 mmHg is the most important consideration in this decision. In some high-altitude regions of China, ECMO treatment is also routinely conducted. The experiences above are derived from low-altitude areas, and whether they apply in high-altitude regions is still being determined. This study aimed to explore the significantly lower membrane lung oxygen uptake in high-altitude regions compared to low-altitude areas.

Interventions

OTHERMonitoring membrane lung function at different altitudes

The altitude in Beijing is 100m, while the altitude in Xining, Qinghai is 2600m. We will monitor the partial pressure of post-ML arterial oxygen in ECMO patients in these two locations and evaluate whether the normal values of membrane lung function are consistent in different altitudes.

Sponsors

Affiliated Hospital of Qinghai University
CollaboratorOTHER
Beijing Chao Yang Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

* Receiving ECMO support

Exclusion criteria

* Unable to obtain post-membrane blood gas * Pregnancy * Patients cannot receive anticoagulation * Refusal to participate in the trial

Design outcomes

Primary

MeasureTime frameDescription
Initial assessment of membrane lung oxygen uptakeOn the third day of ECMO supportO2 content of post-ML blood - O2 content of pre-ML blood

Secondary

MeasureTime frameDescription
60-day mortalityAfter patients enrolled 60 daysMortality rate at 60 days of VV-ECMO support

Countries

China

Contacts

Primary ContactHua Yang, Dr.
xuanben1985@163.com+8618601342030

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026